Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020108642 - CD19-AND CD30-BASED COMBINED CAR-T IMMUNOTHERAPY

Publication Number WO/2020/108642
Publication Date 04.06.2020
International Application No. PCT/CN2019/122160
International Filing Date 29.11.2019
IPC
C12N 5/10 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 15/867 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
867Retroviral vectors
C12N 7/01 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
01Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
A61K 35/17 2015.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 35/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
02specific for leukemia
C07K 14/7051
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
70503Immunoglobulin superfamily
7051T-cell receptor (TcR)-CD3 complex
C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
C07K 16/2803
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2803against the immunoglobulin superfamily
Applicants
  • BEIJING MEIKANG GENO-IMMUNE BIOTECHNOLOGY CO., LTD. [CN]/[CN]
Inventors
  • LI, Yuchen
Agents
  • BEYOND ATTORNEYS AT LAW
Priority Data
201811458441.030.11.2018CN
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CD19-AND CD30-BASED COMBINED CAR-T IMMUNOTHERAPY
(FR) IMMUNOTHÉRAPIE PAR CAR-T COMBINÉE BASÉE SUR CD19 ET CD30
Abstract
(EN)
Provided is an immune cell mixture comprising an immune cell genetically modified with a chimeric antigen receptor targeting CD19 and an immune cell genetically modified with a chimeric antigen receptor targeting CD30 and an application thereof. The chimeric antigen receptor targeting CD19 and the chimeric antigen receptor targeting CD30 each comprises an antigen-binding domain, a transmembrane domain, a costimulatory signaling region, a CD3ζ signaling domain, and an inducible suicide fusion domain in tandem arrangement. The chimeric antigen receptors specifically recognize tumor surface antigens CD19 and CD30. By using the combination of CAR-T cells targeting both antigens, better therapeutic effects are achieved for CD19-negative relapse and B cell tumors with low CD19 expression and the disease is easier to be relieved compared to other single chimeric antigen receptor T cells.
(FR)
L'invention concerne un mélange de cellules immunitaires comprenant une cellule immunitaire génétiquement modifiée avec un récepteur antigénique chimérique ciblant CD19 et une cellule immunitaire génétiquement modifiée avec un récepteur antigénique chimérique ciblant CD30, et une application correspondante. Le récepteur antigénique chimérique ciblant CD19 et le récepteur antigénique chimérique ciblant CD30 comprennent chacun un domaine de liaison à l'antigène, un domaine transmembranaire, une région de signalisation costimulatrice, un domaine de signalisation de CD3ζ, et un domaine de fusion suicide inductible en agencement en tandem. Les récepteurs antigéniques chimériques reconnaissent spécifiquement des antigènes de surface tumorale CD19 et CD30. En utilisant la combinaison de cellules CAR-T ciblant les deux antigènes, de meilleurs effets thérapeutiques sont obtenus quant aux rechutes CD19 négatives et aux lymphomes de type B avec une faible expression de CD19, de plus, la maladie est plus facile à soulager par comparaison avec l'utilisation d'autres lymphocytes T avec récepteur d'antigène chimérique unique.
Also published as
Latest bibliographic data on file with the International Bureau